ライフサイエンスコーパス: methylphenyl

コーパス検索結果 (１語後でソート)

通し番号をクリックするとPubMedの該当ページを表示します

1 no)biphenyl (NPB) and N,N-diphenyl-N,N-bis(3-methylphenyl)-1,1-biphenyl)-4,4-diamine (TPD), respectiv

2 porting efficiency of N,N-diphenyl-N,N-bis(3-methylphenyl)-1,1-biphenyl)-4,4-diamine) (TPD, prototypi

3 When exposed acutely to 1-methyl-4-(2'-methylphenyl)-1,2,3,6-tetrahydrophine (MPTP), mice lacki

4 by the TDZD 4-[(4- fluorophenyl)methyl]-2-(4-methylphenyl)-1,2,4-thiadiazolidine-3,5-dione (CCG-50014

5 ed several novel inhibitors, including 2-4(4-methylphenyl)-1,2-benzisothiazol-3(2H)-one (PBIT), which

6 and its analogs ebselen oxide (EO) and 2-(4-methylphenyl)-1,2-benzisothiazol-3(2H)-one (PT) as inhib

7 methyl}-2H-1,2,3-triazol-4-yl)-2-methyl-5-(3-methylphenyl)-1,3-oxazole-4-carboxamide (ACT-389949), ad

8 trimethyl bicyclo heptan-2-yl]-5-(4-chloro-3-methylphenyl)-1-(4-methylbenzyl)-pyrazole-3-car boxamide

9 ty cannabinoid CB2 antagonist, 5-(4-chloro-3-methylphenyl)-1-[(4-methylphenyl)methyl]-N-[(1S,2S,4R)-1

10 time-dependent inhibition of Icmt by 2-[5-(3-methylphenyl)-1-octyl-1H-indol-3-yl]acetamide (cysmethyn

11 ve small-molecule inhibitor of Icmt, 2-[5-(3-methylphenyl)-1-octyl-1H-indol-3-yl]acetamide (cysmethyn

12 2-(1,1-Dimethylethyl)-2-(4-methylphenyl)[1,3]dioxolane (SAH51-641, 1) has previousl

13 d, 6-chloro-2,3,4,5-tetrahydro-3-methyl-1-(3-methylphenyl)-1H-3-benzazepine-7,8-diol (SKF83959), foun

14 MMP-9) promoter and identified 5-methyl-2-(4-methylphenyl)-1H-benzimidazole (MPBD) inhibitory for MMP

15 ed inhibitors such as 2-(3-bromo-2-hydroxy-5-methylphenyl)-1H-indole-5-carboxamidine, 22a, and 2-(2-h

16 e c-Src inhibitor 1-(1,1-dimethylethyl)-1-(4-methylphenyl)-1H-pyrazolo[3,4-d]pyrimidin-4-amine (PP1)

17 t-butyl)-3-isoxazolyl]aminocarbonyl)amino]-3-methylphenyl-1H-5-p yrazolyl)-4-[(4-methylpiperazino)met

18 methylphenyl), 2,2'-di-tert-butyl-6,6'-bis(2-methylphenyl), 2,2',6,6'-tetrakis(2,6-dimethylphenyl), a

19 PF(6))(2) where Nttpy = 4'-(p-nicotinamide-N-methylphenyl)-2,2':6',2' '-terpyridine, is observed to b

20 es with 6-chloro-7,8-dihydroxy-3-methyl-1-(3-methylphenyl)-2,3,4,5-tetrahydro-1H-3 -benzazepine (SKF8

21 librium with its cyclic isomer 6-phenyl-3-(4-methylphenyl)-2,3-dihydro-1,2,4-triazin-4-oxide (6'), wh

22 (3) C(6) H(2) ; PNC(2-) =(N-(2-P(i) Pr(2) -4-methylphenyl)-2,4,6-CH(2) Me(2) C(6) H(2) ), was prepare

23 u(2) -K}](2) (2) (PN(-) =(N-(2-P(i) Pr(2) -4-methylphenyl)-2,4,6-Me(3) C(6) H(2) ; PNC(2-) =(N-(2-P(i

24 -K(OEt(2))}](2) (1) (PN(-)=(N-(2-P(i)Pr(2)-4-methylphenyl)-2,4,6-Me(3)C(6)H(2)) reductively couples C

25 (N3) (PN(-) = (N-(2-(diisopropylphosphino)-4-methylphenyl)-2,4,6-trimethylanilide), can be reduced wi

26 (SCP) (2) [PN=N-(2-(diisopropylphosphanyl)-4-methylphenyl)-2,4,6-trimethylanilide)].

27 5-chloro-4-((4-chlorophenyl)(cyano)methyl)-2-methylphenyl)-2-hydroxybenzamide ("ZT-1a").

28 3,4-difluorophenoxy)benzyl]-4-piperidinyl}-4-methylphenyl)-2-methylpr opanamide (16g, SNAP 94847) was

29 One of the antagonists, 2-(4-chloro-3-methylphenyl)-2-oxoethyl thiocyanate (CMOT), has been re

30 The lead compound, racemic 1-(4-methylphenyl)-2-pyrrolidin-1-yl-pentan-1-one 4a, was res

31 onoamine uptake inhibition test was 3beta-(4-methylphenyl-2 beta-[5-(3-nitrophenyl)thiazol-2-yl]tropa

32 ex (PNP)Ti=CH(t)Bu(CH3) (PNP=N[2-P(CHMe2)2-4-methylphenyl]2(-)), catalyses the dehydrogenation of cyc

33 t)Bu] (A; PNP(-) identical withN[2-P(i)Pr2-4-methylphenyl]2(-)), dehydrogenates ethane to ethylene at

34 plex (PNP)Nb(CH3)2(OAr) (PNP = N[2-P(i)Pr2-4-methylphenyl]2(-), Ar = 2,6-(i)Pr2C6H3), prepared from t

35 nt behavior of a PNP (PNP- = N[2-P(CHMe2)2-4-methylphenyl]2) pincer ancillary bound to nickel.

36 eCH(t)Bu(CH2(t)Bu) (PNP(-) = N[2-P(CHMe2)2-4-methylphenyl]2) reacts with H2CPPh3 to form the kappa(2)

37 )Bu(CH2(t)Bu) (2; PNP(-) = N[2-P(CHMe2)(2-)4-methylphenyl]2), prepared from the precursor (PNP)Ti[tri

38 )2(OAr)] (M=Zr or Hf; PNP(-)=N[2-P(CHMe2)2-4-methylphenyl]2); Ar=2,6-iPr2C6H3), which were readily pr

39 (mu2-CH3)2[Al(CH3)2]2 (PNP = N[2-P(CHMe2)2-4-methylphenyl]2-) can be prepared from the reaction of (P

40 l(2) (N(t) BuAr)] (1) (PNP=N[2-P(i) Pr(2) -4-methylphenyl](2) (-) ; Ar=3,5-Me(2) C(6) H(3) ) results

41 identical withC(t)Bu (PNP = N[2-P(i)Pr(2)-4-methylphenyl](2)(-)), activates a C-H bond of ethane at

42 (PNP)FeCl(2)] (1) (PNP = N[2-P(CHMe(2))(2)-4-methylphenyl](2)(-)), prepared from one-electron oxidati

43 KF82958), 3-methyl-6-chloro-7,8-hydroxy-1-[3-methylphenyl]-2,3,4,5-tetrahydro-]H-3-b enzazepine (SKF8

44 the most interesting compounds was 3beta-(4-methylphenyl)-2beta-(4-methylphenyl)tropane (3d), which

45 Surprisingly, 3beta-(4-methylphenyl)-2beta-[3-(4'-chlorophenyl)isoxazol-5-yl]tr

46 enyl)isoxazol-5-yl]tropane (3p) and 3beta-(4-methylphenyl)-2beta-[3-(4'-methylphenyl)isoxazol-5-yl]tr

47 ork led to the identification of 1i (4-[5-(4-methylphenyl)-3-(trifluoromethyl)- H-pyrazol-1-yl]benzen

48 4-triazole ligands employed, L(azine) = 4-(4-methylphenyl)-3-phenyl-5-(azine)-1,2,4-triazole, where a

49 ter (DAT) inhibitor, 4-hydroxy-1-methyl-4-(4-methylphenyl)-3-piperidyl 4-methylphenyl ketone (3, K(i)

50 3-(4-Methylphenyl)-3-trimethylsilylcyclopropene and 3-(4-trif

51 rated the dimeric product 3-(2,3-dimethoxy-6-methylphenyl)-4-methyl-1,2-benzoquinone as the major pro

52 e K+-competitive, fluorescent inhibitor 1-(2-methylphenyl)-4-methylamino-6-methyl-2, 3-dihydropyrrolo

53 he atypical ligands AC-42 (4-n-butyl-1-(4-(2-methylphenyl)-4-oxo-1-butyl)piperidine HCl) and 77-LH-28

54 interactions of carbachol, 4-n-butyl-1-[4-(2-methylphenyl)-4-oxo-1-butyl] piperidine hydrogen chlorid

55 4-n-Butyl-1-[4-(2-methylphenyl)-4-oxo-1-butyl]-piperidine hydrogen chlorid

56 allosteric agonists AC-42 (4-n-butyl-1-[4-(2-methylphenyl)-4-oxo-1-butyl]-piperidine hydrogen chlorid

57 ' ' = n-propyl, n-butyl, isobutyl, phenyl, 4-methylphenyl, 4-(dimethylamino)phenyl) to yield the corr

58 4-methoxyphenyl, 3,4-methylenedioxyphenyl, 4-methylphenyl, 4-fluorophenyl, phenyl, 2-thienyl, methyl)

59 methylaminopropionyl)amino-2-methylpropyl]-6-methylphenyl]-4-[(2R )-methyl-3-(4-chlorophenyl)propiony

60 pplication of a selective FFA3 agonist (N-[2-methylphenyl]-[4-furan-3-yl]-2-methyl-5-oxo-1,4,5,6,7,8-

61 2-(4-Amino-3-methylphenyl)-5-fluorobenzothiazole (5F-203) is a candid

62 A candidate antitumor agent, 2-(4-amino-3-methylphenyl)-5-fluorobenzothiazole (5F-203), was empiri

63 The lysyl-amide of 2-(4-amino-3-methylphenyl)-5-fluorobenzothiazole (NSC 710305, 6d) has

64 e anticancer compound (3-amino-N-(3-chloro-2-methylphenyl)-5-oxo-5,6,7,8-tetrahydrothieno[2,3-b]quino

65 1-phenyl-4-(4-methylphenyl)butynone to 2-(4-methylphenyl)-5-phenylfuran displayed first-order kineti

66 ylthioethoxy)-5-(N-methyl- N-h ydroxyureidyl)methylphenyl]-5-(3,4, 5-trimethoxyphenyl)tetrahydrofuran

67 amino}}benzyl]-N,N-dimethyl-N- {{{4-{{{[2-(4-methylphenyl)-6,7-dihydro-5H-benzocycloheptan-8-yl]carbo

68 a CCR5 inhibitor (N,N-dimethyl-N-{{4-{[2-(4-methylphenyl)-6,7-dihydro-5H-benzocyclohepten-8-yl]car b

69 TAK-779 (N,N-dimethyl-N-[4-[[[2-(4-methylphenyl)-6,7-dihydro-5H-benzocyclohepten-8-yl]car b

70 CCR2/CCR5 antagonist N-dimethyl-N-[4-[[[2-(4-methylphenyl)-6,7-dihydro-5H-benzohepten-8-yl] carbonyl]

71 ll lines has been identified as 2-(4-amino-3-methylphenyl)-6-hydroxybenzothiazole (6c).

72 nhibitor of Src family kinases, 4-amino-4-(4-methylphenyl)-7-(t-butyl) pyrazola[3,4-d]pyrimidine, pre

73 se inhibitors, herbimycin A and 4-amino-5-(4-methylphenyl)-7-(t-butyl)pyrazolo-D-3,4-pyrimidine (PP1)

74 ibited by genistein, but not by 4-amino-5-(4-methylphenyl)-7-(t-butyl)pyrazolo[3, 4-d]pyrimidine, a s

75 tein (RAP) or the Src inhibitor 4-amino-5-(4-methylphenyl)-7-(t-butyl)pyrazolo[3,4-d]-pyrimidine (PP1

76 Inhibition of Src with 4-amino-5-(4-methylphenyl)-7-(t-butyl)pyrazolo[3,4-d]-pyrimidine (PP1

77 3-d]pyrimidin-7-one (PD173952), 4-amino-5-(4-methylphenyl)-7-(t-butyl)pyrazolo[3,4-d]pyrimidine (PP1)

78 e populations of the inhibitor, 4-amino-5-(4-methylphenyl)-7-(t-butyl)pyrazolo[3,4-d]pyrimidine (PP1)

79 mine (2MB-PP1) but not by other 4-amino-5-(4-methylphenyl)-7-(t-butyl)pyrazolo[3,4-d]pyrimidine (PP1)

80 nhibitors: Src kinase inhibitor 4-amino-5-(4-methylphenyl)-7-(t-butyl)pyrazolo[3,4-d]pyrimidine (PP1)

81 itors staurosporine (2 microM), 4-amino-5-(4-methylphenyl)-7-(t-butyl)pyrazolo[3,4-d]pyrimidine (PP1,

82 sporine (IC50, 0.06 microM) and 4-amino-5-(4-methylphenyl)-7-(t-butyl)pyrazolo[3,4-d]pyrimidine (PP1;

83 aurosporine and the Lck inhibitor 4-amino-5-(methylphenyl)-7-(t-butyl)pyrazolo[3,4-d]pyrimidine was s

84 urosporine and the Lck inhibitor, 4-amino-5-(methylphenyl)-7-(t-butyl)pyrazolo[3,4-d]pyrimidine.

85 yrosine kinase activation with [4-Amino-5-(4-methylphenyl)-7-(t-butyl)pyrazolo[3,4-d]pyrimidine] or c

86 The Src inhibitor 4-amino-5-methylphenyl-7-(t-butyl)pyrazolo[3,4-d] pyrimidine (PP1)

87 protein-1 inhibitor SR-11302 [3-methyl-7-(4-methylphenyl)-9-(2,6,6-trimethylcyclohexen-1-yl)nona-2,4

88 Chiral (2S)-2-amino-2-substituted-N-(4-methylphenyl)acetamides 12a-d, easily prepared in two st

89 Attachment of a 4-((3-hydroxy-4-methylphenyl)amino) substituent provided potent inhibito

90 late (5Me-HQE), obtained from diethyl 2-[((3-methylphenyl)amino)methylene]malonate.

91 (CTPC), and N-(2-bromophenyl)-N'-{2-[ethyl(3-methylphenyl)amino]ethyl}-urea (SB-452533) exhibiting si

92 The structurally simplified m-methylphenyl analog 1e displayed binding affinity in the

93 (N(t) Bu)(2) ) (1 b) (Ar*=2,6-dibenzhydryl-4-methylphenyl and Mes*=2,4,6-tri-tert-butylphenyl), toler

94 (PNP)V(=NAr)(=CH(2))] (PNP = N[2-P(i)Pr(2)-4-methylphenyl](-), Ar = 2,6-(i)Pr(2)C(6)H(3)), via H atom

95 In the case of 3-methylphenyl azide, the reaction proceeds via the cis/sy

96 4-[2-cyano-5-(3-pyridylmethoxy)phenoxy]-4-(2-methylphenyl)b utanoi c acid (12m).

97 cation of flurandrenolide and 2-methoxy-N-(4-methylphenyl) benzamide (2-MMB) as compounds that reprod

98 2-(4-Amino-3-methylphenyl) benzothiazole (NSC 674495; DF 203) demonst

99 2-(4-Amino-3-methylphenyl)benzothiazole (1a, DF 203, NSC 674495) is a

100 wo fluorine-containing molecules, 4-fluoro-3-methylphenyl boronic acid and 4-fluoro-3-methylphenol, s

101 dependence for the reaction of 1-phenyl-4-(4-methylphenyl)butynone to 2-(4-methylphenyl)-5-phenylfura

102 paste electrode modified by meso-tetrakis(3-methylphenyl) cobalt porphyrin (CP) and TiO(2) nanoparti

103 we were able to measure the acidity of 3-(4-methylphenyl)cyclopropene at the allylic position (delta

104 T-136088 (1-(4'-(3-methyl-4-(((1(R)-(3-(11)C-methylphenyl)ethoxy)carbonyl)amino)isoxazol-5 -yl)-[1,1'

105 Unexpectedly, lithiation of N'-(2-(2-methylphenyl)ethyl)-N,N-dimethylurea with 3 equiv of n-b

106 s for lateral lithiation of tert-butyl (2-(2-methylphenyl)ethyl)carbamate.

107 Similarly, lithiation of N-(2-(2-methylphenyl)ethyl)pivalamide under similar reaction con

108 5S,7R)-5-(3-hydroxypheny l)-4-methyl-2-[2-(2-methylphenyl)ethyl]-2-azabicyclo[3.3.1]non-7-yl}propan a

109 A(2) agonist N6-[2-(3,5-dimethoxyphenyl)-2-(methylphenyl)-ethyl]-adenosine (10 nm).

110 acylglycerol lactones built with a rigid 4-[(methylphenyl)ethynyl]phenyl rod that is separated from t

111 y containing a thin film of 2,7-bis[9,9-di(4-methylphenyl)-fluoren-2-yl]-9,9-di(4-methylphenyl)fluore

112 ,9-di(4-methylphenyl)-fluoren-2-yl]-9,9-di(4-methylphenyl)fluorene.

113 inhibitor HET0016 (N-hydroxy-N'-(4-n-butyl-2-methylphenyl)formamidine) to block 20-HETE synthesis.

114 In contrast, N-hydroxy-N'-(4-butyl-2-methylphenyl)formamidine, a potent inhibitor of 20-HETE

115 Diazo compounds derived from (p-methylphenyl)glycine were screened for the ability to es

116 nsition was accompanied by rotation of the 4-methylphenyl group of the axle component molecule and a

117 at the ATP-binding site of the kinase, and a methylphenyl group on PP1 is inserted into an adjacent h

118 decomposition products, except 2-methyl-6-(4-methylphenyl)-hept-2-en-4-one, have the potential to cro

119 e 7 ([(11)C]RO6924963), N-[(11)C]methyl-2-(3-methylphenyl)imidazo[1,2-a]pyrimidin-7-amine 8 ([(11)C]R

120 -bis[2,6-bis[di(4-tert-butylphenyl)methyl]-4-methylphenyl]imidazol-2-ylidene) CuOPh [(IPr**)CuOPh] re

121 3beta-(4-Chlorophenyl) tropane-2beta-[3-(4'-methylphenyl) isoxazol-5-yl] Hydrochloride (RTI 336), a

122 (3p) and 3beta-(4-methylphenyl)-2beta-[3-(4'-methylphenyl)isoxazol-5-yl]tropane (3r) did not produce

123 j), and 3beta-(4-methoxyphenyl)-2beta-[3-(4'-methylphenyl)isoxazol-5-yl]tropane (9) were synthesized

124 -methylbenzyl)succinate was oxidized to E-(3-methylphenyl)itaconate (or a closely related isomer) and

125 ster) via (3-methylbenzyl)succinate and E-(3-methylphenyl)itaconate (or its CoA thioester) in a serie

126 xy-1-methyl-4-(4-methylphenyl)-3-piperidyl 4-methylphenyl ketone (3, K(i) values of 492 and 360 nM in

127 n of [(PN)(2)Ti=O] (1) [PN = (2-P(ii)Pr(2)-4-methylphenyl)(mesityl)amide] with KC(8) and 2.2.2-crypta

128 1 of alpha-meso-phenylheme-IX, alpha-meso-(p-methylphenyl)-mesoheme-III, and alpha-meso-(p-trifluorom

129 thyl-1-(2-propylheptyl)pyridin-1-ium-4-yl)-3-methylphenyl)meth anide; three-ring 3TTMC, dicyano(4'-(3

130 d on [3-(2,3-dihydro-1,4-benzodioxin-6-yl)-2-methylphenyl]methanol induce an enlarged interaction int

131 ntagonist, 5-(4-chloro-3-methylphenyl)-1-[(4-methylphenyl)methyl]-N-[(1S,2S,4R)-1,3,3-trimet hylbicyc

132 T2 receptors with (S)-1-[4-(dimethylamino)-3-methylphenyl]methyl-5-(diphenylacetyl)- 4, 5,6,7-tetrahy

133 One compound, N-(3-chloro-4-methylphenyl)-N'-[2-[([5-[(dimethylamino)-methyl]-2-fury

134 e antiviral assembly inhibitor N-(3-chloro-4-methylphenyl)-N'-{2-[({5-[(dimethylamino)-methyl]-2-fury

135 tris-(8-hydroxyquinoline)aluminum/N,N'-bis(3-methylphenyl)-N,N'-diphenylbenzidin e) and light detecti

136 e diffusion of ultrathin films of N,N'-Bis(3-methylphenyl)-N,N'-diphenylbenzidine (TPD) (12 nm [Formu

137 of thin vapor-deposited films of N,N'-bis(3-methylphenyl)-N,N'-diphenylbenzidine (TPD) can exceed th

138 ll molecule organic semiconductor N,N'-Bis(3-methylphenyl)-N,N'-diphenylbenzidine.

139 Esterification of GFP with 2-diazo-2-(p-methylphenyl)-N,N-dimethylacetamide was efficient.

140 rop-2-enyl)-2beta-carbofluoroethoxy-3beta-(4'methylphenyl)nor tropane ((18)F-FE-PE2I) is a newly deve

141 doprop-2E-enyl)-2-beta-carbomethoxy-3beta-(4-methylphenyl) nortropane ((123)I-PE2I) in patients with

142 odoprop-2E-enyl)-2beta-carbomethoxy-3beta-(4-methylphenyl)nortropane ((11)C-PE2I) and (11)C-N,N-dimet

143 odopro-2E-enyl)-2beta-carbomethoxy-3beta-(4'-methylphenyl)nortropane).

144 nd selective compound was 3alpha-(3-fluoro-4-methylphenyl)nortropane-2beta-carboxylic acid methyl est

145 ifluoromethyl)phenyl]-2-hydroxyethoxy}-4- (2-methylphenyl)octahydro-2H-isoindol-2-yl]-1,3-oxazol-4(5H

146 (S)-(2-Methylphenyl)phenylphosphine oxide was transformed to a

147 trations that ranged from 20.1 ng/L for tris(methylphenyl) phosphate (TMPP) to 30100 ng/L for tris(2-

148 pecifically, a series of P-stereogenic (aryl)methylphenyl phosphines are shown to undergo rapid racem

149 isolation with an organocatalyst (2-amino-5-methylphenyl phosphonic acid, used to speed up reversal

150 H-DPAT and 1000 or 2000 ng of N-(3-trifluoro-methylphenyl) piperazine hydrochloride (TFMPP) or 2-(1-p

151 in vivo evaluation of Cimbi-712 (3-{4-[4-(4-methylphenyl)piperazine-1-yl]butyl}p-1,3-dihydro-2H-indo

152 isopropyl-4'-(trimethylammonium chloride)-5'-methylphenyl piperidine-1-carboxylate (AMO-1618) and cal

153 r for many analytes compared to a commercial methylphenyl polysiloxane GLC stationary phase.

154 tramesitylporphyrin (TMP) or meso-tetrakis(4-methylphenyl)porphyrin (H(2)T-pMe-PP), and L = a thiol,

155 oxy]ethoxy]ethyl-3-(3-tert-butyl-4-hydroxy-5-methylphenyl)propanoate).

156 for AO1024, and 3-(3-tert-butyl-4-hydroxy-5-methylphenyl) propanoic acid for AO245.

157 AO245 (2-[2-[2-[3-(3-tert-butyl-4-hydroxy-5-methylphenyl)propanoyloxy]ethoxy]ethoxy]ethyl-3-(3-tert-

158 with genistein and 4-amino-1-tert-butyl-3-(p-methylphenyl)pyrazolo[3,4-d] pyrimidine abolished the in

159 the nitrogen and on the CH(2) next to the 2-methylphenyl ring (alpha-lithiation).

160 The 2-methylphenyl substituent imparts linear optical properti

161 henylethyl substituent in 13b and 37a or a 2-methylphenyl substituent in 37b also allowed the resulti

162 The 2,6-dimethylphenyl and 2-methylphenyl substituents impart greater oxidative stabi

163 ,6-dimethylphenyl), and 2,2',6,6'-tetrakis(2-methylphenyl) substituents, respectively, were prepared

164 Simple ortho-methylphenyl substitution boosts the photoluminescence q

165 hibitor 49 [IC50 = 10 nM, 3-[(2-tert-butyl-5-methylphenyl)sulfanyl]-5,6-dihydro-4 -hydroxy-6-phenyl-6

166 ([3-[(1H-benzimidazol-2-ylsulfanyl)methyl]-2-methylphenyl]sulfanyl)ethyl carbamates with the generic

167 plots and Bronsted-type plots of substituted methylphenyl sulfates vs hydrogen peroxide anions and su

168 2-methyl-4-oxo-6-quinazolinyl)methyl)-4-((2- methylphenyl)sulfinyl)-N-(prop-2-ynyl)aniline complexed

169 no acid transporter 2 (SNAT2), 3-(N-methyl(4-methylphenyl)sulfonamido)-N-(2-trifluoromethylbenzyl)thi

170 Two O4-arylsulfonylthymidine precursors, (4-methylphenyl)sulfonyl and (2,4,6-trimethylphenyl)sulfony

171 ltures with the NF-kappaB inhibitor (E)3-[(4-methylphenyl)sulfonyl]-2-propenenitrile (BAY 11-7082) pr

172 sing Lawesson's reagent, producing 1-[[4-[4-(methylphenyl)sulfonyl]-3,4,5,8-tetrahydro-2H-1,4-thiazoc

173 btype, N-ethyl-2-[(6-methoxy-3-pyridinyl)[(2-methylphenyl)sulfonyl]amino]-N-(3-pyridinyl methyl)-acet

174 ption 3 (STAT3) inhibitor 2-hydroxy-4-[[[[(4-methylphenyl)sulfonyl]oxy]acetyl]amino]-benzoic acid (NS

175 x between a hydroxamate, (2R)-2-[(4-fluoro-3-methylphenyl)sulfonylamino]-N-hydroxy-2-(tetrahydro-2H -

176 The sulfur and nitrogen moieties of methylphenyl sulfoximine (MPS)-enabled aryl thioamides a

177 is explicitly viable under the influence of methylphenyl sulfoximine directing group constructing th

178 the aromatic donor group D = 2,5-dimethoxy-4-methylphenyl to be a suitable redox center for the const

179 oxidations of phenyltrimethylstannane and (4-methylphenyl)trimethylstannane by 1,2,4,5-tetracyanobenz

180 ctivities for phenyltrimethylstannane and (4-methylphenyl)trimethylstannane varied by factors of 26 a

181 ompounds was 3beta-(4-methylphenyl)-2beta-(4-methylphenyl)tropane (3d), which showed an IC50 of 1.23

182 ghly specific alpha4beta1 inhibitor 4-((N'-2-methylphenyl)ureido)-phenylacetyl-leucine-aspartic acid-

183 ide-based alpha4beta1 inhibitor (1; 4-[N'-(2-methylphenyl)ureido]phenylacetyl-Leu-Asp-Val) derived fr